Araştırma Makalesi

EVALUATION OF POSSIBLE COMPLICATIONS OF IRRADIATION OF BLOOD PRODUCTS ON PATIENTS

Cilt: 45 Sayı: 2 30 Haziran 2023
PDF İndir
EN TR

EVALUATION OF POSSIBLE COMPLICATIONS OF IRRADIATION OF BLOOD PRODUCTS ON PATIENTS

Abstract

Background: Blood transfusion is a life-saving but high-risk procedure in various medical conditions as it is not a simple fluid infusion but an organ transplant. Although blood transfusions save lives, they may cause serious, life-threatening reactions. Nowadays, the number of reactions has decreased significantly with the reduction of leucocyte content of blood products or their irradiation. Materials and Method: A total of 5582 patients who received irradiated blood products in our hospital between 14/08/2020 and 17/02/2023 were included in the present study. Erythrocyte suspension, platelet apheresis, and pooled platelet suspension were irradiated at doses of 25–30 Gy. Results: A total of 5582 blood products including 4990 erythrocyte suspensions, 282 pooled platelet suspensions, and 310 platelet apheresis were irradiated in the present study. No transfusion-associated Graft Versus Host Disease was identified in any patient included in the present study and there were only mild allergic reactions and febrile non-hemolytic transfusion reactions. Conclusions: Based on the data obtained here from, it was concluded that irradiation of blood products can prevent the highly fatal transfusion-related Graft Versus Host Disease.

Keywords

Destekleyen Kurum

Sivas Cumhuriyet Üniversitesi Bilimsel Araştırma Projeleri koordinasyon birimi (CÜBAP)

Proje Numarası

RGD-035

Teşekkür

Destekleri için Sivas Cumhuriyet Üniversitesi Bilimsel Araştırma Projeleri koordinasyon birimine teşekkür ediyorum

Kaynakça

  1. 1. Karadoğan İ. Transfüzyon komplikasyonları. Bayık M, editör. Kan bankacılığı, transfüzyon tıbbı ve aferez. Hematolog; 2015.s128-140.
  2. 2. Jawa RS, Young DH, Stothert JC, Kulaylat MN, Landmark JD. ‘Transfusion-associated graft versus host disease in the immunocompetent patient: An ongoing problem’, Journal of Intensive Care Medicine, 2015;30(3), pp. 123–130.
  3. 3. LS Del Lama, E Garcia de Go´ es, PC Dias Petchevist, EL Moretto, JC Borges, DT Covas, A de Almeida. Prevention of Transfusion-Associated Graft-versus-Host Disease by Irradiation: Technical Aspect of a New Ferrous Sulphate Dosimetric System. PLoS One. 2013 Jun 7;8(6):e65334. doi: 10.1371/journal.pone.0065334.
  4. 4. Chun S, Phan MTT, Hong S, Yang J, Yoon Y, Han S, Kang J, Yazer MH, Kim J, Cho D. Double-filtered leukoreduction as a method for risk reduction of transfusion-associated graft-versus-host disease.PLoS One. 2020; 15(3): e0229724. doi: 10.1371/journal.pone.0229724.
  5. 5. Kleinman S. and Stassinopoulos A. ‘Transfusion-associated graft-versus-host disease reexamined: potential for improved prevention using a universally applied intervention’, Transfusion. 2018:58(11), pp. 2545–2563. [PubMed: 30267423].
  6. 6. Şencan M. Lökosit Azaltılmış ve Işınlanmış Kan Ürünü Kullanımı. Türkiye Klinikleri J Int Med Sci 2007, 3(36):82-86.
  7. 7. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002;117:275-287.
  8. 8. Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, Saran F, Thurston J, Webbet D. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. British Journal of Haematology. 2010: 152: 35–51.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Sistemleri

Bölüm

Araştırma Makalesi

Erken Görünüm Tarihi

30 Haziran 2023

Yayımlanma Tarihi

30 Haziran 2023

Gönderilme Tarihi

7 Haziran 2023

Kabul Tarihi

24 Haziran 2023

Yayımlandığı Sayı

Yıl 2023 Cilt: 45 Sayı: 2

Kaynak Göster

AMA
1.Terzi H, İnanır M, Yılmaz H, Yurtsever İ, Şencan M. EVALUATION OF POSSIBLE COMPLICATIONS OF IRRADIATION OF BLOOD PRODUCTS ON PATIENTS. CMJ. 2023;45(2):7-12. doi:10.7197/cmj.1310755